^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

INCAGN1949

i
Other names: INCAGN1949, INCAGN01949, INCAGN 01949, INCAGN 1949
Associations
Trials
Company:
Agenus, Incyte
Drug class:
OX40 agonist
Associations
Trials
over1year
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (clinicaltrials.gov)
P1/2, N=2, Terminated, University of Southern California | N=42 --> 2 | Trial completion date: Apr 2024 --> Dec 2022 | Recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Dec 2022; Study drug no longer available
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
vidutolimod (CMP-001) • INCAGN1949
3years
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (clinicaltrials.gov)
P1/2, N=42, Recruiting, University of Southern California | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
vidutolimod (CMP-001) • INCAGN1949
over3years
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (clinicaltrials.gov)
P1/2, N=42, Not yet recruiting, University of Southern California | Trial completion date: Jul 2023 --> Jul 2024 | Initiation date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jul 2022 --> Jul 2023
Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
vidutolimod (CMP-001) • INCAGN1949
over4years
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma (clinicaltrials.gov)
P1/2, N=42, Not yet recruiting, University of Southern California | Trial completion date: Dec 2022 --> Jul 2023
Clinical • Trial completion date • Combination therapy
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
vidutolimod (CMP-001) • INCAGN1949
over4years
Clinical • New P1/2 trial • Combination therapy
|
BRCA (Breast cancer early onset)
|
BRCA mutation
|
vidutolimod (CMP-001) • INCAGN1949